TargetMol se distingue parmi les marques de nos partenaires, qui sont plus de 25

APP-018 (D-4F) is an 18 D-amino acid peptide that mimics apolipoprotein A-I (apoA-I). It enhances the anti-inflammatory properties of high-density lipoprotein (HDL) and is applicable in cardiovascular disease research.

<p>KRL74 is a cyclic peptide inhibitor that interferes with the interaction between the p6 domain of the HIV Gag protein and the UEV domain of the human TSG101 protein (p6/UEV), with an IC50 of 5.44 μM and a Kd of 11.9 μM. It also inhibits the budding of HIV from host cells, exhibiting an IC50 of 2 μM in virus-like particle (VLP) budding assays.</p>

VGB3 is a peptide antagonist of vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2, exhibiting anti-angiogenic and anti-tumor properties. It binds to VEGFR1 and VEGFR2, thereby inhibiting VEGF-driven endothelial cell proliferation, migration, and tube formation, as well as suppressing tumor growth and metastasis in a mouse 4T1 breast cancer model.

SVS-1 peptide is an anticancer peptide that selectively targets cancer cells through electrostatic interactions, disrupting the cell membrane structure and inducing cell death. Unlike antimicrobial peptides, the activity of SVS-1 peptide occurs before the complete neutralization of membrane charges.

<p>T20-M is a precursor peptide with strong binding affinity for UBE2C.</p>

<p>P-ESBP-DOX is an HPMA copolymer-drug conjugate composed of an E-selectin binding peptide and Doxorubicin. It exhibits cytotoxicity against TNFα-activated human vascular endothelial cells (IVEC) with an IC50 of 0.28 μM and is useful for tumor vasculature research.</p>

ATWLPPRAANLLMAAS is a chimeric peptide with anti-angiogenic and potent antitumor capabilities. It effectively inhibits the proliferation, viability, migration, and invasion of human hepatocellular carcinoma cells, and induces apoptosis (apoptosis).

GNQWFI, an anti-Flt1 peptide, functions as a VEGFR1-specific antagonist. It inhibits interactions between VEGFR1 and various ligands, such as VEGFA, VEGFB, and placental growth factor (PIGF), and suppresses VEGF-induced endothelial cell migration and tubulogenesis. GNQWFI holds potential for research in cancer, asthma, and other ocular diseases.

4-Amino-D-phenylalanine ([D-Phe(4-NH2)]) is a cyclic pentapeptide that inhibits the binding of CXCL12 to CXCR4 in FC131, with an IC50 value of 0.1 μM.

DOTA-EB-TATE is formed by combining the SST peptide derivative DOTA-octreotate with an Evans blue analog (EB). This peptide drug conjugate (PDC) enhances the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. Additionally, DOTA-EB-TATE serves in the synthesis/research of radiopharmaceutical conjugates (RDC).

<p>The synthetic compound me4 Peptide, designed from the microexon me4 sequence of the neuronal CPEB4 protein, can inhibit the aggregation of CPEB4 and is applicable in research on autism spectrum disorder-related conditions.</p>

PKHB1 is a thrombospondin-1 peptide mimetic known for its antitumor properties. It induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. Additionally, PKHB1 promotes immune system activation through immunogenic cell death in breast cancer cells.

Octaarginine is a cell-penetrating peptide (CPP) known for its membrane-translocating activity. CPP's inherent ability to enter cells makes it useful for delivering various membrane-impermeable bioactive agents intracellularly. Additionally, CPP is employed to transport antimicrobial agents into intracellular bacteria.

S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 value of 2.53 μM. It selectively targets the active site Cys360 of the enzyme. By inhibiting LSD1 activity, S9-CMC1 TFA elevates H3K4me1 and H3K4me2 levels, inducing G1 cell cycle arrest and apoptosis, thereby suppressing cell proliferation. In addition, S9-CMC1 TFA markedly inhibits tumor growth in A549 xenograft animal models.

<p>Alkyne-βAG-TOCA is an octreotide derivative that targets somatostatin receptor subtype 2 (SST2). It is utilized in the synthesis and research of radioconjugates (RDC).</p>

ZLIRTLHEWY is an effective peptide inhibitor of the CD47/SIRPα interaction, offering potential applications in cancer research.

RI-AG03 is an orally active peptide inhibitor capable of crossing the blood-brain barrier, targeting Tau aggregation. It effectively inhibits Tau aggregation in both in vivo and in vitro models, improving associated neurodegenerative and behavioral phenotypes. RI-AG03 is applicable in research on Tauopathies such as Alzheimer's disease.

Aselacin C is a cyclic peptide that can be isolated from fungi of the Acremonium spp.

FLDKFNHEAEDLFYQSSL is an 18-residue peptide that binds to the SARS-CoV-2 receptor-binding domain (RBD). It inhibits the entry of SARS-CoV-2 and also interacts with binding residues (Leu455, Phe456, Ala475, and Gln493).

<p>NBD peptide inhibits the NF-κB signaling pathway by preventing the binding of the NEMO-IKK complex. It exhibits anti-inflammatory activity by blocking the production of pro-inflammatory cytokines. Additionally, NBD peptide demonstrates immunosuppressive effects through the regulation of immune cells. It enhances transmembrane capacity by conjugating with the cell-penetrating peptide HIV-TAT.</p>

S-palm P0(180–199) (TFA) is a peptide that enhances MHC II-restricted responses. It is utilized to develop models of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and chronic experimental autoimmune neuritis (c-EAN). S-palm P0(180–199) (TFA) is also studied in the context of autoimmune-mediated neuritis.

<p>CyPep-1 is a novel cationic lytic peptide with antitumor activity. It exerts potent cytotoxicity by interacting with the negatively charged membranes of cancer cells. CyPep-1 demonstrates strong cell lytic activity against cancer cells both in vitro and in vivo, making it useful for researching solid tumors.</p>

MciZ is a peptide consisting of 40 amino acids that inhibits the GTPase activity of FtsZ, thereby preventing improper Z-ring formation during the process of sporulation.

PIC1 PA, a peptide consisting of 15 amino acids, serves as an effective analog of PIC1 that inhibits complement activation mediated by the classical pathway. Functionally, PIC1 PA interferes with the interaction between the C1s-C1r-C1r-C1s/MASPs and the collagen-like region (CLR) of C1q/MBL. It specifically binds to the CLR of C1q, with an average equilibrium dissociation constant (KD) of 33.3 nM when binding purified C1q.

HB-3-20 induces the degradation of integrin αVβ5 on the cell surface. Transglutaminase 2 (TG2) specifically interacts with HB-3-20, exhibiting a catalytic efficiency (kcat/KM) of 0.16 μM^-1min^-1.

<p>RI-OR2-TAT is a brain-penetrable inhibitor targeting β-amyloid (β-Amyloid) oligomerization. It is engineered by integrating the HIV protein transduction domain TAT into RI-OR2. RI-OR2-TAT binds to Aβ42 fibrils with a Kd value of 58-125 nM. It reduces Aβ aggregation and plaque levels, diminishes microglial activation and oxidative damage, and enhances the number of young neurons in the dentate gyrus.</p>

p21PBP, a peptide composed of 20 amino acids, serves as an inhibitor of DNA replication. It specifically binds to the purified proliferating cell nuclear antigen (PCNA) found in extracts from tumor cells. p21PBP holds potential for use in cancer research.

SLAFVDVLN is a peptide molecule that functions as a BACE-1 inhibitor, exhibiting a Ki value of 94 nM. Additionally, SLAFVDVLN is capable of reducing the production of Aβ42.

mC46 (C46) peptide is a membrane-associated fusion peptide inhibitor that effectively impedes the replication and entry of HIV-1. Additionally, mC46 peptide can inhibit CCR5-tropic, CXCR4-tropic, and dual-tropic HIVs, as well as SIV and SHIV.

Eloralintide (LY 3841136) is an AMYR agonist, anticipated for research in type 2 diabetes and obesity.

<p>Pt(IV)-M13 is a platinum (IV) prodrug conjugated with a perfluoroaryl macrocyclic peptide, capable of crossing the blood-brain barrier. It exhibits cytotoxicity towards glioblastoma stem cells and enhances platinum uptake in the brain, making it a valuable tool for glioblastoma research.</p>

<p>kCAL01 is a CAL inhibitor with a Ki value of 2.3 μM and holds potential for research in cystic fibrosis (CF).</p>

<p>MAPI is an irreversible peptidyl 3C cysteine protease (SV3CP) inhibitor. By covalently attaching its C-terminal Michael acceptor moiety to the active site thiol of SV3CP Cys 139, MAPI inhibits SV3CP. It shows potential for use in the study of norovirus infections.</p>

R4K1 is a cell-permeable stapled peptide that binds with high affinity to estrogen receptor (ER) α, inhibiting its interaction with coactivators. It penetrates breast cancer cells, regulating gene transcription and suppressing cell proliferation. R4K1 is applicable for tumor research.

<p>PACE4 Inhibitory peptide C23 (Compound C23) is an effective peptidomimetic inhibitor known to act against PACE4. It exhibits antiproliferative effects on PCa cell lines, with a Ki of 5 nM, and IC50 values of 25 μM and 40 μM for DU145 and LNCaP cells, respectively. Additionally, PACE4 Inhibitory peptide C23 suppresses tumor growth in LNCaP xenograft mice.</p>

PD-1/PD-L1 inhibitory peptide C8 disrupts the PD-1/PD-L1 interaction, leading to the activation of CD8+ and CD4+ T cells and an increase in IFN-γ secretion. In mouse models, PD-1/PD-L1 inhibitory peptide C8 has demonstrated antitumor activity.

<p>ANP [Des18-22] 4-23 amide rat is a peptide fragment of rat atrial natriuretic peptide (ANP) that specifically binds to NPR-C.</p>

P160 peptide is a breast cancer-targeting peptide that binds to the keratin 1 (KRT1) receptor in breast cancer cells, with a Kd of approximately 1.1 μM. It shows significant potential for targeted drug delivery to breast cancer cells. P160 peptide enhances the cellular uptake and anticancer activity of the pro-apoptotic antimicrobial peptide MccJ25 (microcin J25). It is applicable in cancer research studies.

<p>Tertomotide (GV1001) hydrochloride is a peptide vaccine composed of a 16-amino acid sequence from human telomerase reverse transcriptase (hTERT). It exhibits neuroprotective properties and has potential for research in Alzheimer's disease.</p>

Bicyclic UK18 is a competitive inhibitor of human urokinase-type plasminogen activator (uPA) with a Ki value of 53 nM.

<p>GPLGLAGGWGERDGS is a polypeptide with MMP enzyme responsiveness and tumor-targeting properties, suitable for research on enzyme-guided nanoparticle assembly within tumors.</p>

<p>Petrelintide (ZP8396) acetate is an amylin analog with potential for weight reduction, suitable for diabetes research.</p>

<p>mcK6A1 serves as an inhibitor of amyloid-β (Aβ) aggregation, selectively binding to the 16KLVFFA21 fragment of Aβ42, leading to the formation of an extended β-sheet structure and preventing the formation of Aβ42 oligomers. This compound is valuable for research into Alzheimer's disease and other amyloid-related disorders.</p>

<p>Poneratoxin acetate is a neurotoxic peptide and modulator of NaV1.6/NaV1.7, lowering the activation threshold of voltage-gated sodium channels and causing pain.</p>

<p>HBpep(RPY)-SP acetate is a modified HBpep-SP peptide directly crosses the cell membrane, intracellular delivery peptides, proteins, and mRNAs, transfection.</p>

<p>APL180 TFA (L-4F) is an apolipoprotein A-I mimetic peptide that enhances the anti-inflammatory properties of high-density lipoprotein (HDL). APL180 is applicable for cardiovascular disease research.</p>

Pegtarazimod (RLS-0071) inhibits the complement system through both the classical and lectin pathways. It suppresses myeloperoxidase (MPO) activity, leading to reduced ROS production, and decreases the formation of neutrophil extracellular traps (NET). Pegtarazimod exhibits anti-inflammatory properties and is applicable in the study of acute graft-versus-host disease.

Salivaricin B is a broad-spectrum bacteriocin produced by Lactobacillus M7, capable of inhibiting the growth of Listeria monocytogenes, Bacillus cereus, Brochothrix thermosphacta, Enterococcus faecalis, and various Lactobacilli.

<p>CK3 peptide is an NRP-1-targeting peptide with the amino acid sequence CLKADKAKC. It specifically binds to NRP-1 to target breast cancer cells. Single-photon emission computed tomography (SPECT) and near-infrared fluorescence (NIRF) imaging demonstrate that CK3 peptide significantly accumulates in xenograft tumors in nude mice. CK3 peptide is applicable for molecular imaging studies of breast cancer.</p>

<p>Ac-MRGDH-NH2 is a pentapeptide containing the RGD sequence. It is utilized in the synthesis of the diastereomeric prodrugs Λ- and Δ-[Ru(Ph2phen)2(κS,κN-(Ac-MRGDH-NH2))]Cl2. In these prodrugs, Ac-MRGDH-NH2 serves as a photolabile protecting group for the cytotoxic diruthenium aqua complexes [Ru(Ph2phen)2(OH2)2]2+, offering integrin targeting and photoactivation properties. Consequently, Ac-MRGDH-NH2 can be applied in studies exploring tumor-targeted photoactivatable chemotherapy.</p>

<p>RSRGVFF (FOXP3 inhibitor P60) is a mixed angiotensin-converting enzyme (ACE) inhibitor with the ability to penetrate the blood-brain barrier, exhibiting an IC50 value of 5.01 μM. It binds to both active and inactive sites of ACE and its substrate HHL complex, thereby reducing the catalytic activity of ACE. RSRGVFF can be further explored for hypertension research.</p>

<p>dCNP binds to NPR-B/C receptors (NPR-B/C receptor), initiating the cGMP signaling pathway and regulating vascular function. It exhibits anti-hypoxic effects by downregulating hypoxia-related genes such as HIF1α and HIF2α. Additionally, dCNP inhibits tumor stroma induction, demonstrating antifibrotic properties. It also enhances immune response by upregulating CTL, NK cells, and conventional type 1 dendritic cells in tumors.</p>

N36Mut(e,g) is an HIV fusion peptide inhibitor targeting gp41. It functions by disrupting the formation of the homotrimeric coiled coil of the N-terminal helix in the pre-hairpin intermediate, leading to the creation of a heterotrimer.

N,S-Bis-Fmoc-Glutathione TFA is a potent inhibitor of glyoxalase II, exhibiting a Ki value of 0.75 μM and an IC50 value of 2.5 μM.

mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to murine CD206, targeting tumor-associated macrophages that express CD206/MRC1. Additionally, mUNO can interact with human recombinant CD206.

Dihydrochlamydocinanalog-1 (compound 2) is a Chlamydocin analog that inhibits the deacetylation of histone H4 peptides, with an IC50 of 30 nM.

<p>LAG-3cyclic peptide inhibitor 12 (Cyclic peptide 12) is an inhibitor of LAG-3, exhibiting an IC50 of 4.45 μM and a Ki of 2.66 µM.</p>

<p>Polyglutamine binding peptide 1 (QBP1) is a peptide inhibitor of polyglutamine (polyQ). It effectively inhibits polyQ protein aggregation in vitro and prevents polyQ-induced cell death in cell cultures.</p>

<p>CT-08 (CT8, Compound 3) is a macrolide Sec61 modulator that inhibits protein secretion in a signal sequence-dependent manner. It prevents the Sec61-mediated translocation of VCAMss-GLuc to the ER, resulting in the loss of luciferase activity. Additionally, CT-08 suppresses the expression of VCAM in transfected cells.</p>

<p>VAMP is a tetrapeptide that acts as a competitive dipeptidyl peptidase IV (DPP-IV) inhibitor, exhibiting an IC50 of 1.00 μM and a Kd of 6.89 μM. It effectively targets the DPP-IV-GLP-1 axis and is utilized in the research of type 2 diabetes.</p>

CPI1 is an effective and highly specific inhibitor of multidrug resistance protein 1 (MRP1). It exhibits inhibitory activity against MRP1 at the nanomolar level (Ki: 100 nM) and has minimal effect on P-glycoprotein (Pgp). CPI1 competes with LTC4 for binding to the same site on MRP1, inhibiting ATP hydrolysis and substrate transport. It is useful in research related to drug delivery and addressing cancer chemotherapy resistance.

PL120131 is a PD-1/PD-L1 inhibitory peptide that disrupts the interaction between PD-1 and PD-L1 by binding to PD-1. This compound can inhibit the apoptosis signaling pathway mediated by PD-1, thereby preventing apoptosis (apoptosis) in Jurkat cells and primary lymphocytes. Additionally, PL120131 supports cytotoxic T lymphocytes (CTL) in exhibiting antitumor activity.

<p>cTEV6-2 covalently inhibits the Tobacco Etch Virus protease (TEV protease) by binding to its cysteine residue (C151), with an IC50 of 81.7 nM.</p>

<p>UK140 is an inhibitor of the urokinase-type plasminogen activator (uPA), with Ki values of 0.20 µM for human uPA (huPA) and 2.79 µM for mouse uPA (muPA). UK140 is applicable in studies related to tumor metastasis.</p>

Liraglutide acetate is the acetate salt form of Liraglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist, utilized in the study of type 2 diabetes.

<p>CRAMP-18 (mouse) is an antibacterial peptide with no hemolytic activity. It exhibits significant inhibitory activity against Gram-negative bacteria, including S. typhimurium and P. aeruginosa. CRAMP-18 (mouse) also shows potential for research in antifungal, antibacterial, and antitumor applications.</p>

Pegevongitide acts as an agonist of the angiopoietin-1 receptor.

Crabrolin is a 13-peptide that can be extracted from the venom of the European hornet (Vespa crabro). Its minimum inhibitory concentration/minimum bactericidal concentration (MIC/MBC) values against Staphylococcus aureus (S. aureus) (NCTC 10788), methicillin-resistant Staphylococcus aureus (MRSA) (NCTC 12493), and Enterococcus faecium (E. faecium) (NTCC 12697) are 2/2, 16/64, and 4/8 μM, respectively.

<p>Corza6 is a potent and selective peptide inhibitor of the human voltage-gated proton channel (hHv1). It binds to the external voltage sensor domain (VSD) loop in hHv1 at a resting membrane potential (RMP) of natural hyperpolarization in mammalian cells with a Kd of approximately 1 nM. Corza6 facilitates sperm capacitation and permits sustained production of reactive oxygen species (ROS) in leukocytes (WBC).</p>

HL2-m5 is an inhibitor of the sonic hedgehog/patched (Shh/PTCH1) interaction, with a Kd for Shh of 170 nM. It effectively inhibits the activation of the Hedgehog signaling pathway and the transcription of Gli-controlled genes, with an IC50 of 230 nM.

The AH-D peptide is an antiviral peptide that selectively disrupts membrane-encased structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.

<p>tLyP-1 peptide is an NRP-1 targeting peptide with an IC50 of 4 μM, and its amino acid sequence is CGNKRTR. It can specifically bind to NRP-1 to target tumor cells.</p>

<p>TAT-N15, a p55PIK inhibitor, demonstrates significant anti-inflammatory and neuroprotective effects. It effectively suppresses the activation of IL-6, IL-8, Akt, and NF-κB pathways, along with the phosphorylation of STAT3 and the protein expression of NF-κB. TAT-N15 is applicable for research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke through its inhibition of Akt, STAT3, and NF-κB pathways.</p>

<p>Na+-Ca2+Exchanger inhibitory peptide (XIP) is an inhibitor of the Na+-Ca2+ exchanger with a Ki of 200 nM. It acts non-competitively to inhibit Na+-dependent Ca2+ uptake and Na+-dependent Ca2+ efflux in sarcolemmal vesicles.</p>

<p>Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. It demonstrates excellent tumor stroma remodeling capabilities and is applicable in research on solid tumors, such as glioblastoma.</p>

<p>ST-CY14 is an inhibitor of the Nur77-PPARγ interaction with an EC50 of 3.15 μM. It binds to Nur77 (Kd=32 nM) to prevent its ubiquitination and degradation by PPARγ, reducing fatty acid uptake and mitochondrial respiration, and inhibiting the transcription of CD36 and FABP4. ST-CY14 suppresses proliferation and migration of MCF7 and MDA-MB-231 cancer cells and impedes tumor growth and bone metastasis in mouse models.</p>

P315V3 is a generic inhibitor of coronaviruses (coronavirus) that effectively suppresses the SARS-CoV-2 prototype PT, Delta, BA.1, and BA.4 strains with IC50 values of 10.9, 8.9, 8.6, and 2.7 nM, respectively. It exhibits cytotoxicity in Vero cells with a CC50 of 4.3 μM and demonstrates anti-infective activity in mouse models.

GRF (1-29) amide (rat) is a synthetic peptide that stimulates the secretion of growth hormone (GH).

CPN-267 (compound 7b) TFA is a selective agonist of neuromedin U receptor 1 (NMUR1) with an EC50 of 0.25 nM. This compound inhibits weight gain in mice and is applicable in obesity research.

<p>H-20 is a PD-1 agonist that reduces the required dosage of morphine for analgesia. It can be used in studies related to chronic pain.</p>

IETP2 targets low-density lipoprotein receptor-related protein 1 (LRP1) with a KD of 738 nM, making it useful for delivering drugs and imaging agents across the blood-labyrinth barrier (BLB).

<p>Atrial natriuretic factor (1-28) (human, porcine) TFA exhibits antihypertensive activity by promoting sodium and urine excretion. It inhibits the release of adrenocorticotropic hormone (ACTH) and β-endorphin by suppressing pro-opiomelanocortin (POMC) expression. Additionally, it elevates cGMP levels in RMIC cells, with an IC50 of 1.2 nM.</p>

<p>ETTAC-2 is an LRG1 PROTAC degrader that facilitates the ubiquitination and degradation of LRG1, with a DC50 of 8.38 µM. It inhibits the TGF-β-Smad3 signaling pathway and reduces the secretion of proteins associated with fibrosis. ETTAC-2 can slow the progression of renal fibrosis.</p>

CPN-351 TFA (compound 9a) is a pentapeptide that acts as a selective antagonist for human NMUR1, exhibiting a pA2 value of 7.35. Its antagonistic effect on human NMUR1 is ten times stronger than on NMUR2. CPN-351 TFA is applicable in inflammation research.

<p>D-CopA3 is an inhibitor of MDM2 and an activator of the p53 signaling pathway. It exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO with IC50 values of 15-18 μM and induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of the cell cycle inhibitor protein p21Cip1/Waf1, enhances mucosal barrier function, and reduces infiltration of inflammatory mediators. It shows anti-inflammatory properties in mouse models of acute enteritis induced by C. difficile toxin A and chronic colitis induced by DSS. Additionally, D-CopA3 demonstrates antitumor activity in a mouse HCT-116 xenograft model.</p>

Alpha 1 Antichymotrypsin, Human Plasma is an inhibitor of serine proteases. This compound is present in amyloid lesions associated with Alzheimer's disease and can be utilized in Alzheimer's research.

HYNIC-UBI29-41 is composed of the bifunctional chelator HYNIC and the antimicrobial peptide UBI 29-41. It retains the antimicrobial properties of UBI 29-41, showing strong affinity for both Gram-positive and Gram-negative bacteria. When labeled with the radioactive element Technetium (99mTc), HYNIC-UBI29-41 can be used as an imaging agent for detecting bacterial infections in mouse models.

<p>GeX-2 is a truncated analogue of αO-conotoxin. It has the ability to activate GABAB receptors and inhibit α9α10nAChR as well as CaV2.2 channels. Additionally, GeX-2 is effective in alleviating pain in a rat model of chronic constriction injury.</p>

<p>Leucylproline hydrochloride is a dipeptide that acts as an exogenous peptide to regulate the synthesis of protease in Lactococcus lactis.</p>

Met-12 is a peptide inhibitor of the Fas receptor. It suppresses Fas receptor-mediated apoptosis in photoreceptor cells and reduces Caspase activation, making it a potential candidate for research on photoreceptor protectants.

<p>Lorutengitide is a transcription-regulating peptide with antiproliferative activity.</p>

<p>Nap-FF is a cell-penetrating dipeptide used in the preparation of hydrogel chemical sensors and for research in targeted drug delivery.</p>

<p>Micafungin metabolite M1 is an active metabolite of Micafungin, generated through metabolism by arylsulfatase, and exhibits antifungal activity. It can be utilized in research on deep fungal infections caused by Candida species (Candidiasis) and Aspergillus species (Aspergillosis).</p>

Nogapendekin alfa inbakicept is an IL-15 superagonist that enhances anti-tumor immune responses by activating NK cells and T cells. It is being studied for use in non-muscle invasive bladder cancer (NMIBC).

H-Pro-Lys-OH TFA is a dipeptide composed of proline and lysine, serving as a substrate for imino dipeptidase (prolinase). Additionally, it can be utilized in peptide synthesis.

DT-3 acetate is a cell-permeable peptide that acts as an inhibitor of protein kinase G (PKGIα), effectively blocking the cGMP-PKG signaling pathway.

<p>RabbitFactor Xa is produced from purified Rabbit Factor X through activation by Russells' Viper Venom, followed by the removal of the venom.</p>

<p>CanineFactor Xa is derived from purified Canine Factor X through activation by Russell's Viper Venom, after which the venom is removed.</p>

<p>SjDX5-271 is a 3 kDa peptide that inhibits the TLR4/MyD88/NF-κB signaling pathway. It induces cell polarization, alleviates liver inflammation, and protects mice from liver ischemia-reperfusion injury.</p>

<p>Zaloganan exhibits broad-spectrum antibacterial activity by disrupting bacterial cell membranes.</p>